Oestrogens and endometrial cancer: a point of view.
The medical profession has been disturbed and bewildered by a number of recent communications which discussed a possible relationship between contraceptive sequential therapy and the incidence of endometrial cancer and between the postmenopausal application of conjugated oestrogens and endometrial carcinoma. An analysis of these reports is made critically and in detail and supplemented with observations on the risk of carcinoma of the breast. The practical aspects are delineated and a precise guide to postmenopausal oestrogen therapy presented.
D000230:Adenocarcinoma / Q000139:chemically induced; D000328:Adult; D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000139:chemically induced; D002979:Climacteric; D003279:Contraceptives, Oral, Sequential / Q000009:adverse effects / Q000627:therapeutic use; D004967:Estrogens / Q000009:adverse effects* / Q000627:therapeutic use; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects; D004970:Estrone / Q000378:metabolism; D005069:Evaluation Studies as Topic; D005260:Female; D005858:Germany; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D012189:Retrospective Studies; D012306:Risk; D014481:United States; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000378:metabolism
D003279:Contraceptives, Oral, Sequential; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D004970:Estrone